title: Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy.
abstract: BACKGROUND
  The current study tested the hypothesis that the clinical outcome of patients with localized esophageal carcinoma after preoperative chemoradiotherapy (CTRT) depends on histology.
  
  
  METHODS
  The authors stratified patients by adenocarcinoma (ACA) or squamous cell carcinoma (SCC) and compared the overall survival (OS) and patterns of failure among patients achieving pathologic complete response (pathCR) and <pathCR after preoperative CTRT. A correlation between baseline clinical stage and posttherapy pathologic response was made for ACA and SCC.
  
  
  RESULTS
  Of the 235 patients who underwent preoperative CTRT, 42 (18%) had SCC and 193 (82%) had ACA. In the ACA group, 56 patients (29%) achieved a pathCR and in the SCC group 13 patients (31%) achieved a pathCR. In the ACA group, a larger proportion of pathCR patients (n=44; 79%) than <pathCR patients (n=82; 60%) were alive at the time of last follow-up (P=0.01) and pathCR patients had a longer OS than <pathCR patients (P=0.0006). However, in the SCC group OS or proportion alive did not differ significantly between pathCR and <pathCR patients (P>or=0.05). In the ACA group, a greater portion of <pathCR patients (32%) than pathCR patients (16%) had distant metastases (P=0.02) and the distant metastases-free survival of pathCR patients was longer than that of <pathCR patients (P=0.0012). In the SCC group, the proportion or time to distant-metastases did not differ significantly. Pretreatment clinical stage did not correlate with pathologic response for either histology.
  
  
  CONCLUSIONS
  The results of the current study suggest that the clinical biology of SCC and ACA is different after CTRT. An investigation of molecular and patient genetics is needed to improve therapy.
authors.affiliation: Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: Pooja R
authors.initials: PR
authors.lastname: Rohatgi
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Swisher
authors.forename: Arlene M
authors.initials: AM
authors.lastname: Correa
authors.forename: Tsung T
authors.initials: TT
authors.lastname: Wu
authors.forename: Zhongxing
authors.initials: Z
authors.lastname: Liao
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Komaki
authors.forename: Garrett L
authors.initials: GL
authors.lastname: Walsh
authors.forename: Ara A
authors.initials: AA
authors.lastname: Vaporciyan
authors.forename: David C
authors.initials: DC
authors.lastname: Rice
authors.forename: Robert S
authors.initials: RS
authors.lastname: Bresalier
authors.forename: Jack A
authors.initials: JA
authors.lastname: Roth
authors.forename: Jaffer A
authors.initials: JA
authors.lastname: Ajani
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D005260:Female; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome